THE OPPORTUNITY
A large, growing pool of stranded assets
The 2021–2025 biotech downturn created an unusually deep bench of underfunded companies holding late-stage assets that failed overall, but retain a credible subgroup story.
A downturn that didn’t just shrink the market — it stranded assets inside it
The 2021–2025 biotech downturn created an unusually deep pool of stranded late-stage assets. Some companies saw Phase 3 trials miss their primary endpoints despite compelling efficacy in defined subpopulations. Others became “zombie biotechs,” trading at or below cash with promising programs but no capital to advance them. The recurring pattern is clear: a viable FDA path forward — and no money to pursue it.
| Indicator | Figure |
|---|---|
| Listed US + EU biotechs, 2021 → 2025 | 977 → 758 |
| Share with < 1 year of cash (end of 2025) | ~33% (~250 companies) |
| Negative-EV / below-cash biotechs (2021 vs. 2019) | 173 vs. 34 |
| New drugs, 2018–21, approved despite missing ≥ 1 primary endpoint | 21 of 210 |
Market-level figures drawn from public reporting; illustrative, not investment advice.
The archetype
A specific setup repeats across the distressed biotech universe: a Phase 3 trial misses its primary endpoint on the overall population, but a pre-specified or FDA-recognized sub-population shows a real, statistically credible effect. The FDA signals that a smaller, targeted confirmatory trial in that sub-population could support approval. The company agrees the path exists — and doesn’t have the cash to run it. This pattern recurs across oncology, CNS, autoimmune and rare disease programs that never got the chance to run their confirmatory study.
This is precisely the gap AllianceXPartners is built to close — not by buying the company, and not by asking it for cash it doesn’t have, but by bringing a funded trial and a compliant site network to the table in exchange for a royalty, a warrant and EAEU rights.
Why it is happening?
Traditional rescue financing often does little to break this cycle. Drip-feeding distressed companies with cash may keep the lights on, fund operations, and cover salaries, but it rarely provides enough capital to advance a late-stage clinical asset to a meaningful value-inflection point. The company survives, but the asset remains stranded. Months later, it must raise again — often at a depressed valuation — further diluting existing shareholders and perpetuating the same destructive financing loop.
AllianceXPartners 